WERFEN RECEIVES US FDA 510(k) CLEARANCE FOR ROTEM® SIGMA COMPLETE CARTRIDGE FOR USE IN TRAUMA

BEDFORD, Mass., Nov. 17, 2026 /PRNewswire/ -- Werfen today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ROTEM sigma complete cartridge to assess peri-operative hemorrhage and/or thrombosis in trauma. The new indication extends the use of the ROTEM sigma viscoelastic testing system beyond cardiovascular surgery and liver transplantation, enabling bleeding management in the trauma setting within the United States. See full Indications for Use below.

Traumatic injury is responsible for approximately 10% of deaths worldwide, and uncontrolled bleeding remains one of the leading causes of potentially preventable death following severe trauma.1–3 Trauma-induced coagulopathy presents an additional challenge, requiring rapid assessment and timely intervention to support patient management.4 Early evaluation of coagulation status is critical in these time-sensitive situations, and current trauma management guidelines recommend viscoelastic testing as part of a goal-directed approach to bleeding management and coagulation support.5–7

Sign up for Blog Updates